文献速递头颈外科

口咽癌放射治疗降剂量后的实践模式与结局

Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer.
PubMed 文献 · Laryngoscope · 2019-05-23

该回顾性数据库研究纳入617例HPV阳性与551例HPV阴性口咽鳞状细胞癌患者,分别有16.9%和15.2%接受了降剂量放疗(<66 Gy);HPV阳性患者中降剂量组与全剂量组生存无显著差异(P = .83),而HPV阴性患者中降剂量组生存显著更差(P = .001)。

要点

  • 在美国,口咽癌降剂量放疗(<66 Gy)的使用率较低,HPV阳性者为16.9%,HPV阴性者为15.2%。
  • HPV阳性患者中,降剂量放疗组与全剂量放疗组的3年和5年生存率无显著差异(P = .83)。
  • HPV阴性患者中,降剂量放疗组的3年和5年生存率显著低于全剂量组(P = .001)。

核心结论

  • 美国口咽鳞状细胞癌降剂量放疗的国家使用率较低(15%-20%),在HPV阳性患者中似乎不影响总生存,但在HPV阴性患者中则不然。
  • 该异质性回顾性分析的注意事项需要多项正在进行的随机试验加以证实。

研究设计与样本

  • 回顾性数据库 review,数据来源于美国国家癌症数据库(National Cancer Database)。
  • 纳入新诊断的口咽鳞状细胞癌患者,排除I/II期、HPV状态未知、接受手术或未接受原发灶外照射放疗、放疗剂量>75 Gy或<54 Gy、放疗疗程<25天或>75天、随访未知或不足(<2个月)者。
  • 共纳入617例HPV阳性患者和551例HPV阴性患者。
  • 采用多变量逻辑回归分析识别与接受降剂量放疗(<66 Gy)相关的变量。
  • 比较HPV阳性和HPV阴性患者中全剂量与降剂量放疗的总生存。

主要发现

  • 降剂量放疗在HPV阳性患者中的使用率为16.9%,在HPV阴性患者中为15.2%。
  • 年龄较大和未接受全身治疗的患者更可能接受降剂量放疗。
  • HPV阳性患者中,降剂量队列的3年和5年生存率分别为83%和80%,全剂量组分别为83%和78%(P = .83)。
  • HPV阴性患者中,降剂量队列的3年和5年生存率分别为29%和23%,全剂量组分别为61%和51%(P = .001)。

局限性

  • 该分析为异质性、回顾性分析,其注意事项需要多项正在进行的随机试验加以证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: Numerous trials are evaluating radiotherapy (RT) de-escalation for human papillomavirus (HPV)-mediated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). Herein, we evaluated the degree to which de-escalated RT is delivered in the United States, as well as comparative outcomes with full-dose RT as stratified for HPV status. STUDY DESIGN: Retrospective database review. METHODS: We identified patients diagnosed with OPSCC in the National Cancer Database, excluding those with stage I/II disease, unknown HPV status, receiving surgery or not receiving external beam radiation therapy to the primary site, receipt of radiation doses >75 or <54 Gy, radiation treatment course duration <25 or >75 days, and unknown or inadequate (<2 months) follow-up. Multivariable logistic regression analysis identified variables associated with delivery of de-escalated RT (<66 Gy). Overall survival of HPV+ and non-HPV-mediated (HPV-) disease was compared between full-dose and de-escalated approaches. RESULTS: Altogether, 617 and 551 patients were HPV+ and HPV-, respectively. De-escalated RT was delivered in 16.9% HPV+ and 15.2% of HPV- disease, respectively. Older patients and omission of systemic therapy were more likely to receive de-escalated RT. In HPV+ patients, 3- and 5-year survival rates were 83% and 80% in the de-escalated cohort versus 83% and 78% in the full-dose group (P = .83). In HPV- patients, corresponding 3- and 5-year survival rates were 29% and 23% versus 61% and 51% (P = .001). CONCLUSIONS: National utilization of de-escalated RT for OPSCC is low (15%-20%), but does not seem to impact overall survival in HPV+ (but not HPV-) patients. The caveats of this heterogeneous, retrospective analysis require corroboration from a number of ongoing randomized trials. LEVEL OF EVIDENCE: 2c Laryngoscope, 130:E171-E176, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. White R, Abel S, Hasan S, et al. Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer. Laryngoscope. 2019. PMID: 31120601. doi:10.1002/lary.28083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。